technology benefits to their coronary patients and their physicians.\u201d<\/span><\/p>\n\u201cThe FDA clearance of the CorPath System will truly change the way I am able to practice. As interventional\u00a0cardiologists, we perform our procedures using X-ray guidance and are cognizant that throughout our careers,\u00a0<\/span>we will be exposed to a high amount of radiation. In the past, we have relied on heavy lead aprons to protect us\u00a0<\/span>from radiation, but the physical stress of wearing these aprons can lead to back pain, fatigue and orthopedic\u00a0<\/span>injuries,\u201d said Joseph P. Carrozza, Jr. M.D., Chief of Cardiovascular Medicine at St. Elizabeth\u2019s Medical Center\u00a0<\/span>in Boston. \u201cRobot-assisted PCI procedures allow us to provide our patients with the highest quality of care\u00a0<\/span>working in an ergonomic position with robotic-assisted stent and balloon placements to restore blood flow.\u201d<\/span><\/p>\n <\/object><\/div>\n<\/div>\n
Recent data published in Catheterization and Cardiovascular Intervention journal demonstrated an\u00a0interventional cardiologist\u2019s daily exposure to radiation and the physical stresses inherent in the cath lab can\u00a0<\/span>lead to occupational health risks, including orthopedic problems, cataracts, and cancer. The CorPath PRECISE\u00a0<\/span>Trial\u2014a prospective, single-arm, multi-center, study, which served as the basis for the submission of a premarket\u00a0<\/span>clearance (510(k)) application to the FDA\u2014 demonstrated that robotically-assisted PCI is safe and\u00a0<\/span>feasible for patients. PCI was successfully completed without having to convert to manual PCI in 98.8 percent\u00a0<\/span>of patients and without device-related complications. The overall procedure success rate was 97.6 percent.<\/span> \n \n<\/span> \nAdditionally, the trial found that robotic-assisted PCI can make the procedure safer for the interventional\u00a0<\/span>cardiologist by reducing the radiation exposure by 95 percent when performing the procedure with the CorPath\u00a0<\/span>200 System.<\/span><\/p>\n\u201cGaining significant experience with the CorPath 200 System, I was impressed with its performance and the\u00a0precise control of the interventional devices, including manipulating the guidewire and stent and being able to\u00a0<\/span>move the devices precisely in increments as small as one millimeter,\u201d said Giora Weisz, M.D., Director of\u00a0<\/span>Clinical Research at the Center for Interventional Vascular Therapy at NewYork-Presbyterian\u00a0<\/span>Hospital\/Columbia University Medical Center and Associate Professor of Medicine at Columbia University\u00a0<\/span>College of Physicians and Surgeons, New York.<\/span><\/p>\n\u201cWorking with this robotic technology is very intuitive and the\u00a0PRECISE trial demonstrated its applicability in today\u2019s cath lab environment. I strongly believe robotic-assisted\u00a0<\/span>PCI will enhance the way we are conducting PCI, and we are looking forward to adapting it in our everyday\u00a0<\/span>practice.\u201d<\/span><\/p>\nThe CorPath 200 System is the first and only robotic-assisted procedure to allow for controlled placement of\u00a0coronary guidewires and stent\/balloon catheters from an optimized interventional cockpit. The lead-lined\u00a0<\/span>cockpit protects the interventional cardiologist from harmful radiation exposure and the seated position in front\u00a0<\/span>of monitors may provide enhanced view of the angiography screen while reducing fatigue and minimizing head,\u00a0<\/span>neck and back strain.<\/span><\/p>\n\u201cThere has been a tremendous amount of interest in the CorPath 200 System, and we are excited to bring to\u00a0market a solution that has the potential to transform the standard of care for PCI procedures,\u201d said Handler.\u00a0<\/span>\u201cCorindus is ready to help our customers successfully implement the complete CorPath-assisted procedure\u00a0<\/span>program into their institutions.\u201d<\/span><\/p>\nAbout Corindus Vascular Robotics<\/strong><\/p>\nCorindus Vascular Robotics (http:\/\/www.corindus.com) is the global technology leader in robotic-assisted\u00a0percutaneous coronary interventions. The Company\u2019s FDA cleared CorPath\u00ae 200 System is the first medical\u00a0<\/span>device that offers interventional cardiologists PCI procedure control from an interventional cockpit. The\u00a0<\/span>CorPath open-platform technology and intellectual property will enable Corindus to address other segments of\u00a0<\/span>the vascular market, including peripheral, neuro and structural heart applications.<\/span><\/p>\n